FAFerhat Gürkan Aslan

Ferhat Gürkan Aslan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ferhat Gürkan Aslan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HIV-1 RNA ve HCV RNA Kantitasyonunda ELITe BeGenius Sisteminin Analitik Performansı: Tanısal Güvenilirliğin Sağlanması

    by Sibel Aydoğan, Saliha Kazci, Ferhat Gürkan Aslan, Bedia Di̇nÇ

    Quantitative detection of human immunodeficiency virus-type 1 (HIV-1) and hepatitis C virus (HCV) RNA plays a crucial role in the diagnosis, monitoring of the therapy and evaluation of the treatment response. The ELITe BeGenius® platform (ELITechGroup, Turin, Italy) is a fully automated sample-toresult molecular system integrating extraction, amplification and detection within a single workflow. The HIV-1 ELITe MGB® and HCV ELITe MGB® assays are real-time polymerase chain reaction tests designed for plasma viral-load quantification. This study aimed to verify their analytical performance under routine clinical laboratory conditions. Verification included assessments of accuracy, intra- and inter-assay precision, linearity and method correlation. A total of 70 plasma samples for HIV-1 RNA and 52 for HCV RNA were analyzed using previously tested and stored patient specimens, reference materials, and external quality controls. Results were compared with established reference assays used in accredited laboratories. Statistical analyses included positive, negative, and overall percent agreement (PPA, NPA, OPA), coefficients of variation (CV%), correlation and regression analyses and Bland-Altman bias estimation. For HIV-1 RNA, 19 of 20 positive and all 20 negative plasma samples were correctly identified by the ELITe MGB® assay, yielding a PPA of 95.0%, NPA of 100.0% and OPA of 97.5% (κ= 0.95). Intra-assay precision showed strong repeatability, with CVs of <1-3.9% for low-positive, 0.4-6.4% for medium-positive and <2% for high-positive specimens. Inter-assay reproducibility was consistent with CVs of 12.8% at low, 2.4% at medium, and 1.4% at high viral loads. Correlation analysis showed excellent concordance with the reference assay (p= 0.975, p< 0.001; R²= 0.95) and a mean bias of -0.40 log10 copies/mL in Bland-Altman analysis. Linearity was strong (R²= 0.97), confirming accurate quantification across the dynamic range with minor underestimation at higher dilutions. For HCV RNA, all 14 positive and 14 negative samples were correctly classified (PPA, NPA, and OPA= 100%; κ= 1.00). Intra-assay precision was excellent, with CVs around 2% for both low- and medium-positive samples, confirming consistent repeatability within a single run. Inter-assay reproducibility was equally robust, with CVs of 0.4-3.3% for low positives, 1.0-2.5% for medium and <1.1% for high-titer specimens. Correlation with the comparator method was strong (r= 0.956, p< 0.001; R²= 0.91) with a mean bias of -0.38 log10 IU/mL. Linearity analysis confirmed high proportionality between expected and measured concentrations (R²= 0.96). Deviations were negligible at low titers and slightly elevated at high loads but remained within acceptable limits. The HIV-1 and HCV ELITe MGB® assays on the BeGenius® platform demonstrated high accuracy, reproducibility and linearity, showing excellent correlation with reference methods. These results confirm that the ELITe BeGenius® system provides reliable and clinically valid viral-load measurements suitable for routine diagnostic use. Comprehensive laboratory verification of molecular assays under real-world conditions is crucial to ensure consistent performance, cross-platform comparability and reliable viral-load monitoring.

  • Microbial isolates and resistance profiles in cerebrospinal fluid cultures: a five-year experience at a tertiary center

    by Merve Gürler, Füsun Kırca, Figen Türen, İrEm Tümkaya Kılınç, Ferhat Gürkan Aslan, Emrah Salman, Nilay Çöplü, Bedia Dinç

    Central nervous system infections are a significant global health concern that results in morbidity and mortality. In case of these infections, empirical antibiotic treatment should be initiated according to the microbiological findings of the cerebrospinal fluid (CSF), and the treatment should be rearranged according to the antibiogram results.The study aimed to determine the distribution of meningitis agents and antimicrobial resistance patterns in our hospital. A total of 17,594 CSF culture samples collected from January 2020 to December 2024 were analyzed retrospectively. The study assessed demographic data, causative microorganisms, and antimicrobial resistance rates. Positive results were found in 7.3% of CSF culture samples, with 69.1% being gram-positive bacteria and 30.9% gram-negative bacteria. The highest positivity rate was detected in the palliative inpatient clinic (14.8%) despite most cultures being from the neonatal intensive care unit (23.5%). The most common microorganisms were coagulase-negative staphylococci(CoNS) (47.9%) and Klebsiella pneumoniae (K.pneumoniae) (9.1%). Methicillin resistance was present in 89.7% of CoNS, and the rate of extended-spectrum β-lactamase-producing strains in K.pneumoniae was 32.4%. Analysis of five-year data revealed the types of microorganisms and their antimicrobial resistance in positive CSF cultures. These findings will guide clinicians in promptly choosing the most effective empirical treatment.


  • COVID-19 Hastalarında Güncel Varyantların Kliniğe Etkisi: EG.5 Varyantının Klinik Özellikleri

    by Ferhat Gürkan Aslan, Süleyman Yalçın, Saliha Kazcı, Bedia Dinç, Gülay Korukluoğlu

    The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has mutated at a high rate since the beginning of the pandemic, leading to the formation of different variants. Alpha, Beta, Gamma, Delta and Omicron have emerged as concerning variants identified by the World Health Organization (WHO). The Omicron variant and its sublineages became dominant worldwide in 2022. EG.5, a sublineage of Omicron, was associated with increased cases recently. In this study, we aimed to investigate the relationship between SARS-CoV-2 variants and the severity of the disease by using the whole genome sequence analysis method in patient samples diagnosed with coronavirus diseases 2019 (COVID-19) in our hospital and to contribute to SARS-CoV-2 surveillance in our country, in the period until the end of 2023, after the announcement of the EG.5 variant. The study included 68 patient samples that were found to be SARS-CoV-2 positive by polymerase chain reaction. Nasopharyngeal/oropharyngeal swab samples obtained from the patients were analysed by syndromic multiplex viral polymerase chain reaction panel. Whole genome sequence analysis was performed on SARS-CoV-2 positive patient samples with high viral load. Barcoded sequencing library was prepared and extracted DNA was sequenced on the Illumina next generation sequencing platform using COVIDSeq test kits (Illumina, USA). The library was loaded into a NextSeq 500/550 high output reagent cartridge v2 75 cycle, NextSeq 500/550 high output flow cell on the NextSeq 550 instrument (Illumina, USA). The DRAGEN COVID lineage programme available in the core domain was used to analyse the sequence data. The resulting combined fasta files were loaded into Nexclade and Pangolin COVID-19 Lineage Assigner programmes and class assignment, mutation calls and sequence quality checks were performed. Statistical evaluation was performed using Statistical Package for Social Sciences (Windows v20.0, Armonk, NY) programme. Sequence results of a total of 68 patients whose SARS-CoV-2 positivity was confirmed in our laboratory and whose samples were suitable for sequence study were analysed with clinical data. While EG.5 variant was detected in 15 (22.1%) of the samples included in the study, different sub-variants other than EG.5 were detected in 53 (77.9%) samples. The first three most frequently detected variants were XBB.1.16, EG.5.1 and FL.1.5.1, respectively. The subtypes of the EG.5 variant were determined as EG.5.1.1, EG.5.1.3, EG.5.1.6 and EG.5.1. Of the patients included in the study, 20 (29.4%) were hospitalised and followed up, 14 of whom had moderate to severe clinical conditions. Four hospitalised patients with comorbidities at an advanced age resulted in exitus. In the statistical evaluation, no significant difference was found between EG.5 and nonEG.5 Omicron variants in terms of age group, clinical symptoms and disease severity. It is recommended to continue genomic surveillance for the timely identification of SARS-CoV-2 and changes in the clinical spectrum and implementation of appropriate countermeasures.

  • COVID-19 Enfeksiyonlarında Dizi Analizi Yöntemlerine Genel Bakış

    by Ferhat Gürkan Aslan, Elmas Pınar Kahraman Kilbaş, Mustafa Altindi̇ş

    Şiddetli akut solunum sendromu koronavirüs 2 (SARS-CoV-2), koronavirüs hastalığı 2019'un (COVID-19) etkeni olarak tanımlandı ve genomik veriler ilk olarak 10 Ocak 2020'de Çin tarafından paylaşıldı. O tarihten itibaren, dünya genelinde toplanan örneklerden viral genomu dizilemek için çok büyük çaba harcandı. Yakın geçmişte, kökenleri izlemek ve bulaşıcı ajanların evrimini anlamak, salgınların yayılma zincirlerini araştırmak, hem etkili ve hızlı moleküler tanı testlerinin geliştirilmesini kolaylaştırmak hem de tedavi ve aşıların araştırılmasına katkıda bulunmak için, yeni nesil dizileme (NGS) stratejileri, başarıyla kullanılmıştır. Teknoloji ve bilimdeki son gelişmeler, COVID-19'un etkeni olan ağır akut solunum sendromu koronavirüsü-2'nin (SARS-CoV-2) genomlarının, bir vakanın tanımlanmasından sonraki saatler veya günler içinde dizilenmesine olanak sağlamıştır. Bu sayede, ilk kez, bir pandeminin halk sağlığı ve epidemi boyutu gerçek zamanlı olarak izlenebilmektedir. SARS-CoV-2 genom dizilerinin erken paylaşımı, moleküler tanı testlerinin hızla geliştirilmesine olanak sağlayarak, küresel hazırlığa ve karşı önlemlerin tasarımına katkıda bulunmuştur. Hızlı, büyük ölçekli virüs genom dizilimi, viral salgınların dinamiklerini anlama ve kontrol önlemlerinin etkinliğini değerlendirmede oldukça önemlidir. SARS-CoV-2 gen dizilimi, gelişmiş tanılar, karşı önlemlerin geliştirilmesi ve hastalık epidemiyolojisinin araştırılması dahil olmak üzere birçok farklı alanda kullanılabilir. COVID-19'un etiyolojik ajanının genomik dizisini tam olarak tanımlamak için etkili ve hızlı dizileme yöntemlerinin geliştirilmesi, tanısal moleküler testlerin tasarımı ve pandemi yayılımını azaltmada etkili önlemlerin alınması ve stratejilerin belirlenmesinde temel olmuştur. Mevcut dizilerin sayısından anlaşıldığı gibi, SARS-CoV-2 genomlarına, farklı yaklaşımlar ve dizileme yöntemleri uygulanabilir. Bununla birlikte, her teknoloji ve dizileme yaklaşımının kendi avantajları ve sınırlamaları vardır. Bu derlemede, SARS-CoV-2 genomlarının dizilenmesi için şu andaki mevcut platformlar ve metodolojik yaklaşımlardan bahsedilecektir.

  • SARS-COV-2 viral load in tears of patients with COVID-19 in the early symptomatic stages: comparison of two different tear sampling methods

    by A. Sonmez, S. Aydın Kurna, F. G. Aslan, F. B. Kaplan, B. Açıkalın, P. Eker

    Purpose To evaluate the presence of SARS-CoV-2 virus in tears of patients with COVID-19 in the early symptomatic stages and to compare two different sampling methods. Materials and method In this cross-sectional study, tears sampling was performed in COVID-19 patients admitted within the first 7 days of symptom onset. The samples were collected with both conjunctival swabs and Schirmer strips. Each specimen was analyzed via RT-PCR. The viral load was evaluated in terms of the cycle threshold value. Ocular and systemic symptoms and comorbidities of the patients were also recorded. Results Forty patients were included. The average time from the initiation of symptoms was 3.15 days. Unilateral conjunctivitis has been observed in 5% of patients and foreign body sensation in 7.5% of patients. No viral RNA was detected in the tear samples of the patients with ocular findings. The positivity rate for SARS-CoV-2 in tears was 2.5% (n = 1). None of the samples collected by Schirmer test strips yielded positive polymerase chain reaction result for SARS-COV-2. The Ct value of the positive conjunctival swab was 36.03 and the nasopharyngeal Ct value of the same patient was 25.68. Conclusion The SARS-CoV-2 viral shedding rate has been determined as 2.5% in the tears of early symptomatic stage COVID-19 patients. The viral load of the tears was lower than the naso-oropharynx. The conjunctival swab method is recommended in tear collection to evaluate the presence of SARS-CoV-2 by RT-PCR analysis in low viral load tears.


  • Relationship Between Viral Load and Prohepcidin Levels in Chronic Hepatitis B Patients

    by Mustafa Altındiş, Ferhat G. Aslan, Kerem Yılmaz, Bilal Toka, Tayfur Demiray, Mehmet Köroğlu

  • Mikrobiyoloji Laboratuvarlarında Çalışan Güvenliği ve Biyogüvenlik Uygulamaları Açısından Türkiye’de Çok Merkezli Bir Değerlendirme

    by Mehmet Köroğlu, Selma Altındiş, Özlem Aydemir, Büşra Yüksel, Tayfur Demiray, Ünal Erkorkmaz, Ferhat Gürkan Aslan, Barış Otlu, Mustafa Altındiş


  • Zeytin Yaprağı Ekstresi ve Propolisin Herpes Simpleks Virüsü Tip 1 Üzerine Antiviral Etkisinin Asiklovir ile Karşılaştırılması

    by Mustafa Altındiş, Ferhat Gürkan Aslan, Hüseyin Uzuner, Havva Ünal, Mehmet Köroğlu, Sedat Kulaç, Aynur Karadenizli


  • microRNA in Patients with Hepatitis B and Hepatitis C Virus Associated Hepatocellular Carcinoma and Cirrhosis

    by Gökhan Küçükkara, Ferhat Gürkan Aslan, Bilal Toka, Mehmet Köroğlu, Mustafa Altındiş